Learn how KMA and LMA represent a breakthrough in treatment approaches for multiple myeloma and related disorders.

Earlier-line bispecific therapy leverages lower disease refractoriness to drive deeper, more durable responses than typically ...

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical-stage biotechnology company focused on the development of ...

Partnership supports development of tumor-activated glycan-directed ADC designed to improve tumor selectivity NEW TAIPEI CITY, Taiwan, March 23, 2026 /PRNewswire/ ...

Epstein-Barr virus antibodies could help differentiate MS from MOGAD and NMOSD. Discover how this biomarker may improve ...

New research suggests the skin does much more than detect damage or keep pathogens out. By tracing how skin cells respond to ...

The team, from biopharmaceutical company Regeneron, hopes their work will help researchers better understand protein-protein interactions during preclinical development of a drug. “Essentially, we ...

Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designed to engage innate immune pathways and complement ...

Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ...

Chronic hepatitis D coinfection affects an estimated 12 million people globally, with higher prevalence in low-income and ...

XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the ...